View Item 

Show simple item record

Chordoma: The Nonsarcoma Primary Bone Tumor

dc.contributor.authorChugh, Rashmi
dc.contributor.authorTawbi, Hussein
dc.contributor.authorLucas, David R.
dc.contributor.authorBiermann, J. Sybil
dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorBaker, Laurence H.
dc.date.accessioned2017-12-15T16:47:54Z
dc.date.available2017-12-15T16:47:54Z
dc.date.issued2007-11
dc.identifier.citationChugh, Rashmi; Tawbi, Hussein; Lucas, David R.; Biermann, J. Sybil; Schuetze, Scott M.; Baker, Laurence H. (2007). "Chordoma: The Nonsarcoma Primary Bone Tumor." The Oncologist 12(11): 1344-1350.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139965
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherBone tumors
dc.subject.otherChordoma
dc.subject.otherProton radiation
dc.titleChordoma: The Nonsarcoma Primary Bone Tumor
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Orthopedic Surgery, University of Michigan, Ann Arbor, Michigan, USA;
dc.contributor.affiliationotherDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
dc.contributor.affiliationotherDepartment of Pathology, and
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology/Oncology,
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139965/1/onco1344.pdf
dc.identifier.doi10.1634/theoncologist.12-11-1344
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceCrockard HA, Cheeseman A, Steel T et al. A multidisciplinary team approach to skull base chondrosarcomas. J Neurosurg. 2001; 95, 184 – 189
dc.identifier.citedreferenceTai PT, Craighead P, Bagdon F, Optimization of radiotherapy for patients with cranial chordoma. A review of dose‐response ratios for photon techniques. Cancer. 1995; 75, 749 – 756
dc.identifier.citedreferenceMunzenrider JE, Liebsch NJ, Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999; 175 suppl 2, 57 – 63
dc.identifier.citedreferenceTai PT, Craighead P, Liem SK et al. Management issues in chordoma: A case series. Clin Oncol (R Coll Radiol). 2000; 12, 80 – 86
dc.identifier.citedreferenceRhomberg W, Bohler FK, Novak H et al. A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlenther Onkol. 2003; 179, 249 – 253
dc.identifier.citedreferenceCrockard A, Chordomas and chondrosarcomas of the cranial base: Results and follow‐up of 60 patients. Neurosurgery. 1996; 38, 420
dc.identifier.citedreferenceFoweraker KL, Chantler HJ, Geater AR et al. Conformal versus IMRT for chordoma of the skull base and cervical spine. Clin Oncol (R Coll Radiol). 2007; 19, S28 – S29
dc.identifier.citedreferenceHug EB, Loredo LN, Slater JD et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999; 91, 432 – 439
dc.identifier.citedreferenceNoel G, Habrand JL, Mammar H et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: The Centre de Protontherapie D’Orsay experience. Int J Radiat Oncol Biol Phys. 2001; 51, 392 – 398
dc.identifier.citedreferenceCastro JR, Linstadt DE, Bahary JP et al. Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys. 1994; 29, 647 – 655
dc.identifier.citedreferenceSchoenthaler R, Castro JR, Petti PL et al. Charged particle irradiation of sacral chordomas. Int J Radiat Oncol Biol Phys. 1993; 26, 291 – 298
dc.identifier.citedreferenceBerson AM, Castro JR, Petti P et al. Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: The Lawrence Berkeley Laboratory experience. Int J Radiat Oncol Biol Phys. 1988; 15, 559 – 565
dc.identifier.citedreferenceFleming GF, Heimann PS, Stephens JK et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer. 1993; 72, 714 – 718
dc.identifier.citedreferenceScimeca PG, James‐Herry AG, Black KS et al. Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol. 1996; 18, 237 – 240
dc.identifier.citedreferenceRazis DV, Tsatsaronis A, Kyriazides I et al. Chordoma of the cervical spine treated with vincristine sulfate. J Med. 1974; 5, 274 – 277
dc.identifier.citedreferenceMcSweeney AJ, Sholl PR, Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordoma therapy. AMA Arch Surg. 1959; 79, 152 – 155
dc.identifier.citedreferenceAzzarelli A, Quagliuolo V, Cerasoli S et al. Chordoma: Natural history and treatment results in 33 cases. J Surg Oncol. 1988; 37, 185 – 191
dc.identifier.citedreferenceChugh R, Dunn R, Zalupski MM et al. Phase II study of 9‐nitro‐camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005; 23, 3597 – 3604
dc.identifier.citedreferenceCasali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer. 2004; 101, 2086 – 2097
dc.identifier.citedreferenceStacchiotti S, Ferrari S, Ferraresi V et al. Imatinib mesylate in advanced chordoma: A multicenter phase II study. J Clin Oncol. 2007; 25 18 suppl Abstract 10003
dc.identifier.citedreferenceTamborini E, Miselli F, Negri T et al. Molecular and biochemical analyses of platelet‐derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 2006; 12, 6920 – 6928
dc.identifier.citedreferenceBurger H, den Bakker MA, Kros JM et al. Activating mutations in c‐KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther. 2005; 4, 1270 – 1274
dc.identifier.citedreferenceCasali PG, Stacchiotti S, Grosso F et al. Adding cisplatin (CDDP) to imatinib (IM) re‐establishes tumor response following secondary resistance to IM in advanced chordoma. J Clin Oncol. 2007; 25 18 suppl Abstract 10038
dc.identifier.citedreferenceWeinberger PM, Yu Z, Kowalski D et al. Differential expression of epidermal growth factor receptor, c‐Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg. 2005; 131, 707 – 711
dc.identifier.citedreferenceHof H, Welzel T, Debus J, Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie. 2006; 29, 572 – 574
dc.identifier.citedreferenceSchonegger K, Gelpi E, Prayer D et al. Recurrent and metastatic clivus chordoma: Systemic palliative therapy retards disease progression. Anticancer Drugs. 2005; 16, 1139 – 1143
dc.identifier.citedreferenceJemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57, 43 – 66
dc.identifier.citedreferenceMcMaster ML, Goldstein AM, Bromley CM et al. Chordoma: Incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001; 12, 1 – 11
dc.identifier.citedreferenceJ Mirra, S Nelson, Rocca C Della, et al. Chordoma. In CD Fletcher, K Unni, F Mertens, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone, Lyon, France: IARC Press, 2002, 316 – 317.
dc.identifier.citedreferenceKlingler L, Trammell R, Allan DG et al. Clonality studies in sacral chordoma. Cancer Genet Cytogenet. 2006; 171, 68 – 71
dc.identifier.citedreferenceBaratti D, Gronchi A, Pennacchioli E et al. Chordoma: Natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003; 10, 291 – 296
dc.identifier.citedreferencePena CE, Horvat BL, Fisher ER, The ultrastructure of chordoma. Am J Clin Pathol. 1970; 53, 544 – 551
dc.identifier.citedreferenceHiginbotham NL, Phillips RF, Farr HW et al. Chordoma. Thirty‐five‐year study at Memorial Hospital. Cancer. 1967; 20, 1841 – 1850
dc.identifier.citedreferenceCatton C, O’Sullivan B, Bell R et al. Chordoma: Long‐term follow‐up after radical photon irradiation. Radiother Oncol. 1996; 41, 67 – 72
dc.identifier.citedreferenceChambers PW, Schwinn CP, Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol. 1979; 72, 765 – 776
dc.identifier.citedreferenceCasali PG, Stacchiotti S, Sangalli C et al. Chordoma. Current Opin Oncol. 2007; 19, 367 – 370
dc.identifier.citedreferenceRiva P, Crosti F, Orzan F et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer. 2003; 107, 493 – 497
dc.identifier.citedreferenceKlingler L, Shooks J, Fiedler PN et al. Microsatellite instability in sacral chordoma. J Surg Oncol. 2000; 73, 100 – 103
dc.identifier.citedreferenceBridge JA, Pickering D, Neff JR, Cytogenetic and molecular cytogenetic analysis of sacral chordoma. Cancer Genet Cytogenet. 1994; 75, 23 – 25
dc.identifier.citedreferenceSandberg AA, Bridge JA, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet. 2003; 143, 1 – 31
dc.identifier.citedreferenceEisenberg MB, Woloschak M, Sen C et al. Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg Neurol. 1997; 47, 156 – 160 discussion 160–161
dc.identifier.citedreferenceButler MG, Sciadini M, Hedges LK et al. Chromosome telomere integrity of human solid neoplasms. Cancer Genet Cytogenet. 1996; 86, 50 – 53
dc.identifier.citedreferenceButler MG, Dahir GA, Hedges LK et al. Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas. Cancer Genet Cytogenet. 1995; 85, 51 – 57
dc.identifier.citedreferenceBoriani S, Bandiera S, Biagini R et al. Chordoma of the mobile spine: Fifty years of experience. Spine. 2006; 31, 493 – 503
dc.identifier.citedreferenceTzortzidis F, Elahi F, Wright D et al. Patient outcome at long‐term follow‐up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery. 2006; 59, 230 – 237 discussion 230–237
dc.identifier.citedreferenceBergh P, Kindblom LG, Gunterberg B et al. Prognostic factors in chordoma of the sacrum and mobile spine: A study of 39 patients. Cancer. 2000; 88, 2122 – 2134
dc.identifier.citedreferenceBosma JJ, Pigott TJ, Pennie BH et al. En bloc removal of the lower lumbar vertebral body for chordoma. Report of two cases. J Neurosurg. 2001; 94 2 suppl 284 – 291
dc.identifier.citedreferenceBas T, Bas P, Prieto M et al. A lumbar chordoma treated with a wide resection. Eur Spine J. 1994; 3, 115 – 117
dc.identifier.citedreferenceHeary RF, Vaccaro AR, Benevenia J et al. “En‐bloc” vertebrectomy in the mobile lumbar spine. Surg Neurol. 1998; 50, 548 – 556
dc.identifier.citedreferenceHsu KY, Zucherman JF, Mortensen N et al. Follow‐up evaluation of resected lumbar vertebral chordoma over 11 years: A case report. Spine. 2000; 25, 2537 – 2540
dc.identifier.citedreferenceSundaresan N, Steinberger AA, Moore F et al. Indications and results of combined anterior‐posterior approaches for spine tumor surgery. J Neurosurg. 1996; 85, 438 – 446
dc.identifier.citedreferenceFujita T, Kawahara N, Matsumoto T et al. Chordoma in the cervical spine managed with en bloc excision. Spine. 1999; 24, 1848 – 1851
dc.identifier.citedreferenceCotler HB, Cotler JM, Cohn HE et al. Intrathoracic chordoma presenting as a posterior superior mediastinal tumor. Spine. 1983; 8, 781 – 786
dc.identifier.citedreferenceKeisch ME, Garcia DM, Shibuya RB, Retrospective long‐term follow‐up analysis in 21 patients with chordomas of various sites treated at a single institution. J Neurosurg. 1991; 75, 374 – 377
dc.identifier.citedreferenceRich TA, Schiller A, Suit HD et al. Clinical and pathologic review of 48 cases of chordoma. Cancer. 1985; 56, 182 – 187
dc.identifier.citedreferenceAnegawa T, Rai M, Hara K et al. An unusual cervical chordoma: CT and MRI. Neuroradiology. 1996; 38, 466 – 467
dc.identifier.citedreferenceMurphy JM, Wallis F, Toland J et al. CT and MRI appearances of a thoracic chordoma. Eur Radiol. 1998; 8, 1677 – 1679
dc.identifier.citedreferenceDucou le Pointe H, Brugieres P, Chevalier X et al. Imaging of chordomas of the mobile spine. J Neuroradiol. 1991; 18, 267 – 276
dc.identifier.citedreferenceSmolders D, Wang X, Drevelengas A et al. Value of MRI in the diagnosis of non‐clival, non‐sacral chordoma. Skeletal Radiol. 2003; 32, 343 – 350
dc.identifier.citedreferenceBilsky MH, Yamada Y, Yenice KM et al. Intensity‐modulated stereotactic radiotherapy of paraspinal tumors: A preliminary report. Neurosurgery. 2004; 54, 823 – 830 discussion 830–831
dc.identifier.citedreferenceNoel G, Habrand JL, Jauffret E et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol. 2003; 179, 241 – 248
dc.identifier.citedreferenceBjornsson J, Wold LE, Ebersold MJ et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993; 71, 735 – 740
dc.identifier.citedreferenceLogroscino CA, Astolfi S, Sacchettoni G, Chordoma: Long‐term evaluation of 15 cases treated surgically. Chir Organi Mov. 1998; 83, 87 – 103
dc.identifier.citedreferencePark L, Delaney TF, Liebsch NJ et al. Sacral chordomas: Impact of high‐dose proton/photon‐beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys. 2006; 65, 1514 – 1521
dc.identifier.citedreferenceDevin C, Chong PY, Holt GE et al. Level‐adjusted perioperative risk of sacral amputations. J Surg Oncol. 2006; 94, 203 – 211
dc.identifier.citedreferenceCheng EY, Ozerdemoglu RA, Transfeldt EE et al. Lumbosacral chordoma. Prognostic factors and treatment. Spine. 1999; 24, 1639 – 1645
dc.identifier.citedreferenceHabrand IL, Austin‐Seymour M, Birnbaum S et al. Neurovisual outcome following proton radiation therapy. Int J Radiat Oncol Biol Phys. 1989; 16, 1601 – 1606
dc.identifier.citedreferenceDebus J, Hug EB, Liebsch NJ et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys. 1997; 39, 967 – 975
dc.identifier.citedreferencePai HH, Thornton A, Katznelson L et al. Hypothalamic/pituitary function following high‐dose conformal radiotherapy to the base of skull: Demonstration of a dose‐effect relationship using dose‐volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001; 49, 1079 – 1092
dc.identifier.citedreferenceSlater JD, Austin‐Seymour M, Munzenrider J et al. Endocrine function following high dose proton therapy for tumors of the upper clivus. Int J Radiat Oncol Biol Phys. 1988; 15, 607 – 611
dc.identifier.citedreferenceCummings BJ, Hodson DI, Bush RS, Chordoma: The results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys. 1983; 9, 633 – 642
dc.identifier.citedreferenceAustin‐Seymour M, Munzenrider J, Goitein M et al. Fractionated proton radiation therapy of chordoma and low‐grade chondrosarcoma of the base of the skull. J Neurosurg. 1989; 70, 13 – 17
dc.identifier.citedreferenceIgaki H, Tokuuye K, Okumura T et al. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys. 2004; 60, 1120 – 1126
dc.identifier.citedreferenceNoel G, Feuvret L, Calugaru V et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005; 44, 700 – 708
dc.identifier.citedreferenceSchulz‐Ertner D, Nikoghosyan A, Thilmann C et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 2004; 58, 631 – 640
dc.identifier.citedreferenceTerahara A, Niemierko A, Goitein M et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys. 1999; 45, 351 – 358
dc.identifier.citedreferenceWeber DC, Rutz HP, Pedroni ES et al. Results of spot‐scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys. 2005; 63, 401 – 409
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco1344.pdf
Size:
613.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.